Newsroom

SAN DIEGO--(BUSINESS WIRE)--UCB, a global biopharmaceutical company, today announced signing of a definitive agreement under which it would acquire Candid Therapeutics (Candid), a privately held clinical-stage biotechnology company redefining the treatment of autoimmune and inflammatory diseases through novel T-cell engagers (TCEs). This transaction supports UCB’s ambition to bring differentiated solutions to people with severe immune-mediated diseases by focusing on areas of high unmet need an...

CALGARY, Alberta--(BUSINESS WIRE)--AltaLink announces Public Safety Power Shut-off no longer required for village of Hughenden and surrounding area....

LOS ANGELES--(BUSINESS WIRE)--The Milken Institute’s 29th annual Global Conference opens today, May 3, 2026, and runs through May 6, 2026, at The Beverly Hilton and Waldorf Astoria Beverly Hills in Los Angeles. Held under the theme Leading in a New Era, the conference convenes more than 1,000 speakers and 4,000 participants across health, finance, business, government, technology, philanthropy, and culture to translate recent disruption and innovation into practical solutions for a more sustain...

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) oggi ha annunciato che la Food and Drug Administration (FDA) statunitense ha approvato Jakafi XR™ (ruxolitinib) compresse a rilascio prolungato per il trattamento di pazienti adulti affetti da mielofibrosi (MF) intermedia o ad alto rischio; gli adulti affetti da policitemia vera (PV) che hanno avuto una risposta inadeguata o sono intolleranti alla idrossiurea; oltre ad adulti e bambini di età minima 12 anni con malattia da trapianto contro...

WILMINGTON, Delaware, USA--(BUSINESS WIRE)--Wie Incyte (Nasdaq:INCY) heute mitteilte, hat die US-amerikanische Arzneimittelbehörde FDA (Food and Drug Administration) Jakafi XR™ (Ruxolitinib) Retardtabletten für die Behandlung von Erwachsenen mit Myelofibrose mit intermediärem oder hohem Risiko, Erwachsenen mit Polycythaemia vera (PV), die unzureichend auf Hydroxycarbamid angesprochen haben oder dieses nicht vertragen, sowie Erwachsenen und Kindern ab 12 Jahren mit steroidrefraktärer akuter Graf...

WILMINGTON, Delaware--(BUSINESS WIRE)--Incyte (Nasdaq : INCY) a annoncé aujourd’hui que la Food and Drug Administration (FDA) des États-Unis a approuvé les comprimés à libération prolongée Jakafi XR™ (ruxolitinib) pour le traitement des adultes atteints de myélofibrose (MF) à risque intermédiaire ou élevé ; aux adultes atteints de polycythémie vraie (PV) ayant présenté une réponse insuffisante à l’hydroxyurée ou ne la tolérant pas ; ainsi qu’aux adultes et aux enfants âgés de 12 ans et plus att...

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) heeft vandaag bekendgemaakt dat de Amerikaanse Food and Drug Administration (FDA) Jakafi XR™ (ruxolitinib) tabletten met vertraagde afgifte heeft goedgekeurd voor de behandeling van volwassenen met myelofibrose (MF) met een gemiddeld of hoog risico; volwassenen met polycythemia vera (PV) die een ontoereikende respons toonden op hydroxyurea of dit middel niet verdragen; evenals volwassenen en kinderen van 12 jaar en ouder met steroïd-refrac...

WILMINGTON, Delaware--(BUSINESS WIRE)--Incyte (Nasdaq: INCY) ha anunciado hoy que la Administración de Alimentos y Medicamentos de Estados Unidos (FDA) ha aprobado Jakafi XR™ (ruxolitinib) en comprimidos de liberación prolongada para el tratamiento de adultos con mielofibrosis (MF) de riesgo intermedio o alto; adultos con policitemia vera (PV) que no han respondido adecuadamente a la hidroxiurea o que no la toleran; así como adultos y pacientes pediátricos a partir de 12 años con enfermedad de...

SAN FRANCISCO--(BUSINESS WIRE)--Planet Labs PBC (NYSE: PL), a leading provider of daily data and insights about change on Earth, today announced the successful launch of three additional Pelican satellites, one of which is the first satellite to orbit as part of the recently-announced satellite services agreement with the Swedish Armed Forces (SwAF). The spacecraft were launched to orbit aboard the CAS500-2 rideshare mission with SpaceX from Vandenberg Space Force Base in California. Planet has...

SALT LAKE CITY--(BUSINESS WIRE)--NomosLogic, Inc., the molecular medicine infrastructure company, today launched two new consumer experiences on Dendrite Lite, available now at lite.dendrite.com. Lyceum is the first personalized genomic literacy quiz built from a user’s own biology. Odyssey tells the story of a user’s genome in seven chapters, in language anyone in the family can understand. Both go live today inside Theogony, the new engagement layer in Dendrite Lite. “This is the moment I hav...